UY37686A - Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables - Google Patents

Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables

Info

Publication number
UY37686A
UY37686A UY0001037686A UY37686A UY37686A UY 37686 A UY37686 A UY 37686A UY 0001037686 A UY0001037686 A UY 0001037686A UY 37686 A UY37686 A UY 37686A UY 37686 A UY37686 A UY 37686A
Authority
UY
Uruguay
Prior art keywords
delivery systems
drug delivery
sustained release
trackable
linkers
Prior art date
Application number
UY0001037686A
Other languages
English (en)
Inventor
M Adams Christopher
Myriam April
Jutta Forster Cornelia
Charles HALL Edward
Tanzina Fazal
Chuck-Munn Lee Cameron
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62116508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37686(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37686A publication Critical patent/UY37686A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En este documento se describen sistemas de entrega del fármaco para administrar agentes biológicamente activos que comprenden aminas primarias o secundarias, o un átomo de nitrógeno del anillo de un anillo de azaheteroarilo, sales farmacéuticamente aceptables de los mismos, reactivos de administración de fármacos relacionados con los mismos, composiciones farmacéuticas que comprenden los sistemas de entrega del fármaco y el uso de los sistemas de entrega del fármaco como agentes terapéuticos de liberación sostenida.
UY0001037686A 2017-04-20 2018-04-19 Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables UY37686A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487888P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
UY37686A true UY37686A (es) 2018-11-30

Family

ID=62116508

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037686A UY37686A (es) 2017-04-20 2018-04-19 Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables

Country Status (26)

Country Link
US (3) US10751417B2 (es)
EP (1) EP3612233A1 (es)
JP (1) JP7323453B2 (es)
KR (1) KR20190137888A (es)
CN (1) CN110603060A (es)
AR (1) AR111481A1 (es)
AU (1) AU2018255933B2 (es)
BR (1) BR112019021810A2 (es)
CA (1) CA3057590A1 (es)
CL (1) CL2019002969A1 (es)
CO (1) CO2019011577A2 (es)
CR (1) CR20190479A (es)
CU (1) CU20190082A7 (es)
DO (1) DOP2019000268A (es)
EA (2) EA201992484A1 (es)
EC (1) ECSP19075134A (es)
IL (1) IL269991B2 (es)
JO (1) JOP20190245A1 (es)
MA (1) MA50260A (es)
MX (1) MX2019012447A (es)
PE (2) PE20191837A1 (es)
PH (1) PH12019502325A1 (es)
SG (1) SG11201908740VA (es)
TW (1) TW201842935A (es)
UY (1) UY37686A (es)
WO (1) WO2018193408A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6833811B2 (ja) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 荷電イオンチャネル遮断薬及び使用方法
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3937945A4 (en) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
US10968179B2 (en) 2019-03-11 2021-04-06 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MA55320A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3986479A1 (en) * 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254617A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
US11795320B2 (en) * 2019-09-20 2023-10-24 Bausch + Lomb Ireland Limited Grafted polymer and use thereof
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2021091585A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN111110829A (zh) * 2019-12-24 2020-05-08 浙江大学 一种纳米防御素凝胶支架及其制备方法和应用
AU2021236130A1 (en) 2020-03-11 2022-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN111285736A (zh) * 2020-04-09 2020-06-16 郑州先利达化工有限公司 含亚磷酸钾、矿源黄腐酸钾、聚谷氨酸的药肥组合物
CN114129780B (zh) * 2020-09-03 2022-06-28 天津大学 一种光控释放一氧化氮的复合水凝胶的制备及应用
WO2023034299A1 (en) * 2021-08-31 2023-03-09 The Research Foundation For The State University Of New York Shear-thinning hydrogels and uses thereof
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CN115074402B (zh) * 2022-07-20 2022-11-18 点滴(南京)生物科技有限公司 一种采用酶法合成的γ-聚谷氨酸钠交联水凝胶及其合成方法
WO2024073588A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115947956B (zh) * 2022-10-09 2024-03-19 西北农林科技大学 一种基于细菌纤维素纳米晶的皮克林纳米乳液及应用
US12064467B2 (en) 2022-10-28 2024-08-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of humanin or other peptides
WO2024146902A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma A/S Methods of producing hydrogel microspheres
WO2024146920A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma Ophthalmology Division A/S Drug conjugates for the treatment of ocular disorders
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69530553T2 (de) 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
AU6419899A (en) 1998-10-09 2000-05-01 Regents Of The University Of Michigan, The Hydrogels and water soluble polymeric carriers for drug delivery
JP2004524297A (ja) 2001-01-23 2004-08-12 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US9290617B2 (en) 2005-07-06 2016-03-22 Molly S. Shoichet Method of biomolecule immobilization on polymers using click-type chemistry
US20070060658A1 (en) 2005-08-31 2007-03-15 Diaz David D Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
UA97953C2 (uk) 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
BRPI0807483A2 (pt) 2007-02-09 2014-05-13 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8053457B2 (en) 2007-03-29 2011-11-08 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
CN102124424A (zh) 2008-01-31 2011-07-13 安普赛德股份有限公司 数据输入装置、数据输入方法和数据输入程序及记录有该程序的记录介质
ES2904673T3 (es) 2008-02-01 2022-04-05 Ascendis Pharma As Profármaco que comprende un conjugado de fármaco-enlazador.
DK3216803T3 (da) 2008-06-25 2020-06-02 Novartis Ag Stabile og opløselige antistoffer, der hæmmer vegf
CN102272120B (zh) 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
WO2010099818A1 (en) 2009-03-03 2010-09-10 Ao Technology Ag Thermoreversible polysaccharide hydrogel
WO2010102663A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Piperazine derivatives for use in therapy
IN2012DN00352A (es) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
WO2011012721A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Carrier linked pramipexole prodrugs
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
SG177761A1 (en) 2009-07-31 2012-03-29 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
RU2558847C9 (ru) 2009-10-29 2016-07-20 Асцендис Фарма Ас Стерилизация биоразлагаемых гидрогелей
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011136645A1 (en) 2010-04-27 2011-11-03 Stichting Katholieke Universiteit, More Particularly Radboud University Nijmegen Fused cyclooctyne compounds and their use in metal-free click reactions
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
EP2678326B1 (en) 2011-02-25 2017-08-02 University of Massachusetts Medical School Monomers and polymers for functional polycarbonates and poly (ester-carbonates) and peg-co-polycarbonate hydrogels
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
EP2716662A4 (en) 2011-05-31 2014-11-19 Univ Tokyo HYDROGEL AND METHOD FOR ITS MANUFACTURE
WO2012173952A1 (en) 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
EP2741738A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Sustained release composition of prostacyclin
KR102109067B1 (ko) 2011-09-07 2020-05-13 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
EP2753607B1 (en) 2011-09-09 2016-04-13 Berry And Associates, Inc. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
JP2014528465A (ja) 2011-10-12 2014-10-27 アセンディス ファーマ オフサルモロジー ディヴィジョン エー／エス 眼の状態の予防及び治療
CA2857548A1 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted enzyme compounds and uses thereof
JP2013116858A (ja) 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Ｂｄｎｆ様低分子化合物を含有する治療薬
US20150037311A1 (en) 2011-12-01 2015-02-05 Angiochem Inc. Targeted lysosomal enzyme compounds
BR112014028588B1 (pt) 2012-05-18 2023-03-21 United Kingdom Research And Innovation Polipeptídeo, método de produzir um polipeptídeo que compreende o grupo bcn, método de produzir um polipeptídeo que compreende um grupo tetrazina, aminoácido e bcn lisina
CA2884910C (en) * 2012-10-11 2021-07-13 Ascendis Pharma Ophthalmology Division A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
AU2013328785B2 (en) 2012-10-11 2016-07-21 Ascendis Pharma A/S Hydrogel prodrugs
CA2885169C (en) 2012-10-11 2021-06-22 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
WO2014059446A1 (en) 2012-10-12 2014-04-17 Case Western Reserve University Biodegradable hydrogel for polynucleotide delivery
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP2925256A4 (en) 2013-01-22 2016-08-17 Prolynx Llc SEALANTS HAVING CONTROLLED DEGRADATION
CN115925957A (zh) * 2013-02-08 2023-04-07 Irm责任有限公司 用于修饰抗体以制备免疫缀合物的特定位点
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
CA2907830C (en) 2013-04-22 2022-03-29 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
WO2014173762A1 (en) 2013-04-22 2014-10-30 Ascendis Pharma A/S Modified hydrogels
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104292454B (zh) * 2013-07-17 2017-12-01 北京键凯科技股份有限公司 聚乙二醇‑环辛炔衍生物
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
WO2015013165A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
CN105612174A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的二硫化物环状多肽
JP2016172783A (ja) 2013-08-08 2016-09-29 生化学工業株式会社 組織膨隆材
CA2924661A1 (en) 2013-10-08 2015-04-16 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-linked il-1ra prodrug
KR20160075665A (ko) 2013-10-22 2016-06-29 프로린크스 엘엘시 소마토스타틴 및 그 유사체의 컨쥬게이트
AU2014345511A1 (en) 2013-11-11 2016-05-12 Ascendis Pharma A/S Relaxin prodrugs
CA2940550C (en) 2014-02-26 2023-01-17 University Of Massachusetts Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof
EP3193941B1 (en) 2014-08-06 2024-05-22 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016025752A1 (en) 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
BR112017014560A2 (pt) 2015-01-09 2018-01-02 Ascendis Pharma Growth Disorders As profármacos de cnp
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
EP3303365A4 (en) 2015-05-29 2019-04-24 Ascendis Pharma Inc. PRODRUGS WITH A PYROGLUTAMATE LINKER
KR20180085761A (ko) 2015-11-20 2018-07-27 크리스탈 딜리버리 비.브이. 능동 타겟팅 나노입자
AU2017234680A1 (en) 2016-03-16 2018-10-11 Prolynx Llc Extended release conjugates of exenatide analogs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط

Also Published As

Publication number Publication date
IL269991B2 (en) 2023-07-01
AU2018255933B2 (en) 2021-09-30
RU2019136872A3 (es) 2021-08-31
JOP20190245A1 (ar) 2019-10-15
CR20190479A (es) 2019-11-20
CO2019011577A2 (es) 2019-10-31
IL269991A (es) 2019-12-31
AR111481A1 (es) 2019-07-17
SG11201908740VA (en) 2019-11-28
IL269991B1 (en) 2023-03-01
AU2018255933A1 (en) 2019-10-17
JP2020517623A (ja) 2020-06-18
CL2019002969A1 (es) 2020-02-07
MA50260A (fr) 2020-02-26
MX2019012447A (es) 2020-01-13
CN110603060A (zh) 2019-12-20
EA201992484A1 (ru) 2020-02-25
ECSP19075134A (es) 2019-10-31
US20180303945A1 (en) 2018-10-25
EA202192099A3 (ru) 2022-02-28
DOP2019000268A (es) 2020-02-16
JP7323453B2 (ja) 2023-08-08
CU20190082A7 (es) 2020-10-20
EP3612233A1 (en) 2020-02-26
PE20211281A1 (es) 2021-07-19
KR20190137888A (ko) 2019-12-11
US10751417B2 (en) 2020-08-25
EA202192099A2 (ru) 2021-11-30
BR112019021810A2 (pt) 2020-05-26
PE20191837A1 (es) 2019-12-30
CA3057590A1 (en) 2018-10-25
US20200376129A1 (en) 2020-12-03
US20230201353A1 (en) 2023-06-29
TW201842935A (zh) 2018-12-16
RU2019136872A (ru) 2021-05-21
PH12019502325A1 (en) 2020-07-06
WO2018193408A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
UY37686A (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
CO2021004012A2 (es) Administración sostenida de polipéptidos similares a la angiopoyetina 3
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
CR20180184A (es) Compuestos heteroarilo y su uso como fármacos terapéuticos
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CU20160166A7 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
CO2021012559A2 (es) Compuestos macrocíclicos como agonistas de sting
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
CL2019002899A1 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4.
UY36958A (es) Compuestos para administración intracelular

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231103